Literature DB >> 7430364

Quantitation of C3 subcomponents on red cells coated with complement in vitro.

J Freedman, A Massey.   

Abstract

In order further to characterise and evaluate the reproducibility of human red cells coated with complement in vitro, the number of molecules of C3 subcomponents/red cell were determined by Scatchard analysis of equilibrium concentrations of bound and free antibody using (125)I-labelled goat anti-rabbit IgG. A 1:1 combining ratio was assumed. Red cells coated via the classical pathway had twice as much bound C3b and C3d as alternative pathway-coated cells. Assays using different anti-C3d sera gave different amounts of bound antigen, but results with any one antiserum versus one cell type were reproducible. Anti-C3d sera raised to C3d-tryp and to C3d-KAF detected significantly different amounts of bound C3d on the same cells. Both trypsinisation and serum KAF treatment of classical pathway-coated cells resulted in marked reduction of C3b molecules/cell (over 90% in both cases). Similar reduction in bound C3b was seen after trypsinisation of alternative pathway-coated cells, but serum KAF treatment of such cells had no significant effect. K(0) values were lower with anti-C3c than with anti-C3d. Anti-C3d K(0) values with the various cells coated with complement in vitro were not statistically different (approximately 10(7) litres/mol), with the exception of trypsinised alternative pathway-coated cells (approximately 10(8) litres/mol, the same order of magnitude observed with cells coated with C3d in vivo). A non-linear relationship between antiglobulin titre and antigen strength was observed. The minimal number of C3d molecules/red cell detectable by agglutination with the various anti-C3d sera ranged from 200 to 670 molecules. The minimal number of C3b molecules detectable by agglutination was approximately 9000 molecules/cell.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7430364      PMCID: PMC1146298          DOI: 10.1136/jcp.33.10.977

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  12 in total

1.  Evaluation of commercial antiglobulin sera over a two-year period. Part I. Anti-beta 1A, anti-alpha 2D, and anti-beta 1E levels.

Authors:  P D Issitt; C H Issitt; S L Wilkinson
Journal:  Transfusion       Date:  1974 Mar-Apr       Impact factor: 3.157

2.  The significance of red cell bound complement components in development of standards and quality assurance for the anti-complement components of antiglobulin sera.

Authors:  G Garratty; L D Petz
Journal:  Transfusion       Date:  1976 Jul-Aug       Impact factor: 3.157

3.  Clinical usefulness of specific antiglobulin reagents in autoimmune hemolytic anemias.

Authors:  H Chaplin
Journal:  Prog Hematol       Date:  1973

4.  Detection of bound C3 by a new immunochemical methods.

Authors:  T Borsos; E J Leonard
Journal:  J Immunol       Date:  1971-09       Impact factor: 5.422

5.  Quantification of antibodies to the C3d subcomponent of human C3.

Authors:  H Chaplin; J Freedman; N C Hughes-Jones
Journal:  Immunology       Date:  1977-06       Impact factor: 7.397

6.  Preparation of red cells coated with C4 and C3 subcomponents and production of anti-C4d and anti-C3d.

Authors:  J Freedman; P L Mollison
Journal:  Vox Sang       Date:  1976-10       Impact factor: 2.144

7.  Autoimmune haemolytic anaemias. 3. Preparation and examination of specific antisera against complement components and products, and their use in serological studies.

Authors:  C P Engelfriet; K W Pondman; G Wolters; D Beckers; G Misset-Groenveld; J J van Loghem
Journal:  Clin Exp Immunol       Date:  1970-05       Impact factor: 4.330

8.  Correlations between quantitative assay of red cell-bound C3, serologic reactions, and hemolytic anemia.

Authors:  J T Fischer; L D Petz; G Garratty; N R Cooper
Journal:  Blood       Date:  1974-09       Impact factor: 22.113

9.  The use of purified 125-I-labelled anti-gamma globulin in the determination of the number of D antigen sites on red cells of different phenotypes.

Authors:  E Rochna; N C Hughes-Jones
Journal:  Vox Sang       Date:  1965 Nov-Dec       Impact factor: 2.144

10.  Measurement of the third component of complement bound to red blood cells in patients with the cold agglutinin syndrome.

Authors:  G L Logue; W F Rosse; J P Gockerman
Journal:  J Clin Invest       Date:  1973-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.